

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

New Programs: Durvalumab for Locally Advanced NSCLC (ULULADUR)

Drug Update

Biosimilar Trastuzumab Available; Antiemetic Premedication Change; Patient Assistance Programs

Provincial Systemic Therapy Program

Revised Policy: Oncology Biosimilars Utilization [III-190]

Drug Shortages

Updated: Raltitrexed; **Resolved:** Tamoxifen

Cancer Drug Manual[®]

New: Durvalumab; **Revised:** Pembrolizumab, Rituximab, Trastuzumab; **Retired:** Aprepitant, Metoclopramide, Ondansetron, Prochlorperazine; CDM Writer Update

Benefit Drug List

New: ULULADUR; **Revised:** GIPNEVER, GIPNSUNI, GIREGO, SAAVGR, SANADENO, SATEMBEV

New & Revised Protocols, PPPOs and Patient Handouts

New: ULULADUR; **Revised:** BRAJAC, BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJDAC, BRAJDCARBT, BRAJFEC, BRAJFEC, BRAJFEC, BRAJFECDT, BRAJTDC, BRAJTR, UBRAJTTW, BRAVAC, UBRAVPALAI, BRAVPAM, BRAVPTRAD,

BRAVPTRAT, UBRAVRIBAI, BRAVTCAP, BRAVTPCARB, BRAVTR, BRAVTRAD, BRAVTRAP, BRAVTRVIN, BRLAACD, BRLAACDT, BRLATACG, BRLATWAC, GIAVPG, GIENDO2, GIFIRINOX, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVCOXT, GIGAVEOCAP, GIGAVEOF, GIGAVFFOXT, GIGAVRAMT, GIGAVTR, GIGECC, GIPAJFIROX, GIPNEVER, GIPNSUNI, GIREGO, GOBEP, GOCISP, GOCXAJCAT, GOEP, GOOVCS, GOSMCCRT, GUAJPG, GUAVPG, GUBEP, GUBGEM, GUBMITO, GUEDPM, GUEP, GUMVAC, GUNAJPG, GUPLHRH, HNAVFUP, HNAVPC, HNAVPC, HNAVPC, HNAVPE, HNAALTPRT, UHNLADCF, HNLAPRT, HNNAVFUP, HNNAVPE, HNNAVPG, HNNLAPG, HNSAVFAC, HNSAVFUP, HNSAVNP, HNSAVPAC, LUAJNP, LUAVDC, LUAVPG, LUAVPP, LUMMPG, LUMMPP, LUOTCAV, LUOTPC, LUSCCAV, LUSCPI, LYAVBD, ULYBRENTUX, LYCHOP, LYCHOPR, LYCHOPRMTX, LYCODOXMR, LYEPOCHR, LYGDP, LYGDPR, LYHDMTXR, LYIVACR, ULYNIV, ULYNIV4, ULYVENETO, ULYVENETOR, UMYDARBD, SAAI, SAAI3, SAAJADIC, SAAJAP, SAAVADIC, SAAVAP, SAAVGR, SAAVI, SAAVI3, SAAVIME3, SADTIC, SAIME, SANADENO, SATEMBEV, SAVAC, SAVDC, SAVDCM, SCNAUSEA, USMAJNIV, USMAJNIV4, USMAVPEM, SMDTIC

Resources and Contact Information

Editor's Choice

New Programs

Effective 01 February 2020, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment program. The full details of this program can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Lung

Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (ULULADUR) — The BC Cancer Lung Tumour Group is introducing durvalumab, a PD-L1 checkpoint inhibitor, for patients with locally advanced stage III unresectable non-small cell lung cancer (NSCLC). Patients are eligible for durvalumab only if their disease has not progressed following at least two cycles of curative-intent, platinum-based chemoradiation therapy.¹ No standard treatment options previously existed for this patient population, whose disease is likely to recur following first-line chemoradiation. A BC Cancer Compassionate Access Program (CAP) approval is required.

Approval of this new treatment program is based on the randomized, double-blind, placebo-controlled

Editor's Choice

phase III PACIFIC trial.² Durvalumab was associated with a significantly longer median progression-free survival (17.2 mo vs. 5.6 mo, HR 0.51, 95% CI 0.41-0.63). The rate of grade 3 or 4 adverse events was similar between the two treatment groups (30.5% vs. 26.1%). The most frequent adverse events leading to treatment discontinuation were pneumonitis (4.8% vs. 2.6%), radiation pneumonitis (1.3% vs. 1.3%) and pneumonia (1.1% vs. 1.3%).

References

1. Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC). Final recommendation for durvalumab (Imfinzi®) for non-small cell lung cancer. 03 May 2019.
2. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med* 2018;379:2342-2350. doi: [10.1056/NEJMoa1809697](https://doi.org/10.1056/NEJMoa1809697)

Drug Update

Biosimilar Trastuzumab Available

Effective 01 February 2020, the BC Cancer Provincial Systemic Therapy Program is implementing the use of biosimilar trastuzumab for select trastuzumab-containing treatment protocols. The trastuzumab biosimilars Herzuma® and Trazimera® are eligible for reimbursement by BC Cancer. A third biosimilar trastuzumab brand, Ogivri®, will not be reimbursed. BC Cancer regional centres will stock Herzuma® as the designated biosimilar.

BC Cancer Document Updates

- Breast and Gastrointestinal document revisions are noted in the *Revised Protocols, PPPOs and Patient Handouts* table at the end of the newsletter.
- A **Pharmacy Selection Box** has been added to trastuzumab-containing **PPPOs**:

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
trastuzumab		

- **Trastuzumab Monograph, Patient Handout and Chemotherapy Preparation and Stability Chart** – Revisions are specified in the *Cancer Drug Manual* section below.
- **Oncology Biosimilars Utilization Policy [III-190]** – Updates are noted in the *Provincial Systemic Therapy Program* announcement below.

Funding

- For treatment starting on or after 01 February 2020, only biosimilar trastuzumab will be funded.
- The reference biologic, Herceptin®, will continue to be funded for all patients who started a planned course of treatment prior to 01 February 2020. A treatment plan may consist of a trastuzumab-containing chemotherapy regimen (e.g., BRAJACTT, BRAVTRAD, GIGAVCCT), followed by single-agent trastuzumab given in a sequential regimen (e.g., BRAJTR, BRAVTR, GIGAVTR).
- All patients on combination pertuzumab and trastuzumab in the advanced setting will continue to receive the reference biologic, Herceptin®, regardless of start date (BRAVPTRAD and BRAVPTRAT).
- Full funding details were announced in the [December 2019](#) issue of the Systemic Therapy Update.

Antiemetic Premedication Change

Effective 01 February 2020, **netupitant-palonosetron** plus dexamethasone will replace aprepitant and ondansetron plus dexamethasone as the standard antiemetic regimen at BC Cancer for patients receiving **highly-emetogenic chemotherapy (HEC)**. The impetus for this practice change comes as a result of a recent update in PharmaCare Limited Coverage policy (see the [January 2020](#) issue of the Systemic Therapy Update for details). Netupitant-palonosetron is a fixed-dose combination product containing 300 mg netupitant (a NK₁ receptor antagonist – NK₁ RA) and 0.5 mg palonosetron (a 5-HT₃ receptor antagonist – 5-HT₃ RA). Due to its long duration of action, netupitant-palonosetron 300 mg-0.5 mg is given orally as a single dose pre-chemotherapy only, with no need for additional doses of NK₁ or 5-HT₃ RA post-chemotherapy.

BC Cancer Document Updates

- **Protocols and Pre-Printed Orders (PPPOs)** have been updated with netupitant-palonosetron as an antiemetic option; revisions are noted in the *Revised Protocols, PPPOs and Patient Handouts* table at the end of the newsletter. Aprepitant has also been removed from the documents. Ondansetron remains an option for patients not requiring a NK₁ RA. The standard antiemetic options in the **PREMEDICATIONS** section of HEC protocols now include:
 - netupitant-palonosetron (plus dexamethasone)
 - ondansetron (plus dexamethasone)
- The BC Cancer Guideline for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults ([SCNAUSEA](#)) has been updated. The **'pre-chemotherapy'** administration time has been clarified as **'30-60 minutes prior to the start of chemotherapy'**. Information on multiday chemotherapy regimens, as well as the use of dexamethasone with anthracycline/cyclophosphamide-based regimens, has also been added.
- A BC Cancer prescription template for netupitant-palonosetron plus dexamethasone is forthcoming.
- Patient education materials for supportive care medications may not be available from BC Cancer, but are accessible from alternate sources. BC Cancer Systemic Therapy Policy III-160 – Selecting Patient Medication Handouts guides the selection of patient handouts from resources such as [Lexicomp](#) or [MedlinePlus](#).

PharmaCare and Prescribing

- The **PharmaCare Collaborative Prescribing Agreement (CPA)** for netupitant-palonosetron has replaced the aprepitant CPA. Oncologists who have signed the new CPA may prescribe netupitant-palonosetron without the need to complete PharmaCare Special Authority (SA) request forms for individual patients.
- PharmaCare SA coverage will continue until 01 August 2020 for patients prescribed aprepitant under the aprepitant CPA prior to 01 February 2020. A new SA request will be required for continued coverage beyond 01 August 2020.
- For patients granted non-CPA SA approval for aprepitant before 01 February 2020, and for all new aprepitant-treated patients after 01 February 2020, prescribers must submit a manual SA request.
- PharmaCare resources include: [Special Authority](#), [Collaborative Prescribing Agreement](#) (link in Practitioner Exemptions section) and [BC PharmaCare Newsletter](#) (Nov 26, 2019 issue, page 4).

Drug Update

Manufacturer Patient Assistance Programs

The listing of patient assistance programs offered by pharmaceutical manufacturers has been updated and can be accessed directly at www.bccancer.bc.ca/mpap. It can also be found on the BC Cancer website under Health Professionals > Systemic Therapy > [Reimbursement & Forms](#).

Provincial Systemic Therapy Program

Revised Policy: Oncology Biosimilars Utilization [III-190]

The BC Cancer Provincial Systemic Therapy Program has updated **Policy III-190 – Oncology Biosimilars Utilization** to include biosimilar trastuzumab. Information about the BC Cancer implementation of biosimilar trastuzumab is found above in the *Drug Update* section. For full details about Policy III-190, please see the [November 2019](#) issue of the Systemic Therapy Update. All Systemic Therapy policies can be found on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#).

Drug Shortages

Full details about new, ongoing or resolved drug shortages, including recommended treatment alternatives, can be found in the briefing notes and/or email communications previously circulated to BC Cancer and the Community Oncology Network (CON).

Updated

Raltitrexed

(Adapted from BC Cancer email communication 22Jan2020)

Raltitrexed is available on allocation and mitigation strategies can now be lifted.

Resolved

Tamoxifen

(Adapted from BC Cancer email communication 13Jan2020)

Tamoxifen supplies are now available.

Cancer Drug Manual[©]

BC Cancer Drug Monographs, Patient Handouts and the Chemotherapy Preparation and Stability Chart can be accessed from the [Cancer Drug Manual[©]](#).

New Documents

The **Durvalumab** Interim Monograph has been updated to the full **Monograph**, and the **Patient Handout** has been developed. Expert review was provided by Dr. Angela Chan (medical oncologist) and Alysha Bharmal (pharmacist) of the BC Cancer Lung Tumour Group. The full monograph contains expanded sections, including *Pharmacokinetics* and *Special Precautions*. Durvalumab is a PD-L1 checkpoint inhibitor that has been implemented at BC Cancer for the treatment of patients with NSCLC (see *Editor's Choice* for ULULADUR announcement). The usual dose is 10 mg/kg IV administered every 2 weeks. Durvalumab was previously added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **Hazardous Drug List**.

Highlights of these documents include:

- infusion-related reactions are reported in up to 2% of patients
- immune-related adverse events may be life threatening; prompt management is important and may include withholding durvalumab, and administering systemic corticosteroids and/or supportive care
- severe infections such as sepsis have been reported

Revised Documents

Highlights of key changes are listed below:

Trastuzumab Monograph, Patient Handout and Chemotherapy Preparation and Stability Chart

Uses: added brand names for all available biosimilars

Supply and Storage: added brand-specific information for all available biosimilars

Patient Handout: added brand names for all available biosimilars

Chemotherapy Preparation and Stability Chart: added brand-specific information for all biosimilars

Chemotherapy Preparation and Stability Chart

Pembrolizumab: updated Merck brand with extended stability

Rituximab: updated product stability in NS and D5W

Retired Documents

Aprepitant, Metoclopramide, Ondansetron and Prochlorperazine Patient Handouts have been retired.

CDM Writer Announcement

The Cancer Drug Manual[©] writing team would like to bid farewell to exiting CDM writer **Lisa Wanbon** who will be returning to her clinical pharmacist position at BC Cancer – Victoria. The team would like to thank Lisa for her many contributions to the Cancer Drug Manual[©] during her secondment as a writer. The team would also like to extend a warm welcome to the new CDM writer, **Alysha Bharmal**. Alysha is a clinical pharmacist at BC Cancer – Surrey. Welcome Alysha!

Benefit Drug List

New Programs

Effective 01 February 2020, the following new treatment program has been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Locally Advanced Non-Small Cell Lung Cancer using Durvalumab	ULULADUR	Restricted

Revised Programs

Effective 01 February 2020, the following treatment programs have been transferred to Class I status on the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Everolimus	GIPNEVER	Class I <i>(previously Restricted)</i>
Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Sunitinib	GIPNSUNI	Class I <i>(previously Restricted)</i>
Treatment of Advanced Hepatocellular Carcinoma using Regorafenib	GIREGO	Class I <i>(previously Restricted)</i>
Third-Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST) using Regorafenib	SAAVGR	Class I <i>(previously Restricted)</i>
Denosumab for Neoadjuvant Use in Patients with Non-Metastatic Operable Giant Cell Tumour of the Bone	SANADENO	Class I <i>(previously Restricted)</i>
Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma using Temozolomide and Bevacizumab	SATEMBEV	Class I <i>(previously Restricted)</i>

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

New Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
ULULADUR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Durvalumab

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
BRAJAC	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide
BRAJACT	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel
BRAJACTG	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Doxorubicin and Cyclophosphamide followed by Paclitaxel
BRAJACTT	<i>Trastuzumab brand name removed; Protocol Title updated; AST replaced with ALT</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel and Trastuzumab
BRAJACTTG	<i>Trastuzumab brand name removed; Protocol Title updated; AST replaced with ALT</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Doxorubicin and Cyclophosphamide followed by Paclitaxel and Trastuzumab
BRAJACTW	-----	<i>Antiemetics updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Early Breast Cancer using Doxorubicin and Cyclophosphamide followed by Weekly Paclitaxel

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
BRAJDAC	-----	<i>Antiemetics updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, Doxorubicin and Docetaxel
BRAJDCARBT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin and Trastuzumab
BRAJFEC	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECD	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel
BRAJFECDT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated; AST replaced with ALT; Institutional name and logo updated</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab
BRAJTDC	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	-----	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Trastuzumab, Docetaxel and Cyclophosphamide
BRAJTR	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Adjuvant Therapy for Breast Cancer using Trastuzumab following the Completion of Chemotherapy (Sequential)
UBRAJTTW	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; AST replaced with ALT</i>	<i>Trastuzumab brand name removed</i>	Adjuvant Therapy for Breast Cancer using Weekly Paclitaxel and Trastuzumab
BRAVAC	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Palliative Therapy for Metastatic Breast Cancer using Doxorubicin and Cyclophosphamide
UBRAVPALAI	<i>Dose Modifications clarified (hematological)</i>	-----	-----	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist

Revised Protocols, PPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPO	Patient Handout	Protocol Title
BRAVPAM	<i>Dose Modifications clarified (renal dysfunction)</i>	-----	-----	Prevention of Skeletal-Related Events Secondary to Breast Cancer Metastases using Pamidronate
BRAVPTRAD	-----	<i>'No substitution' instruction added to trastuzumab (HERCEPTIN®)</i>	-----	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN®) and Docetaxel as First-Line Treatment for Advanced Breast Cancer
BRAVPTRAT	-----	<i>'No substitution' instruction added to trastuzumab (HERCEPTIN®)</i>	-----	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN®) and Paclitaxel as First-Line Treatment for Advanced Breast Cancer
UBRAVRIBAI	<i>Dose Modifications clarified (hematological)</i>	-----	-----	Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with or without LHRH Agonist
BRAVTCAP	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	-----	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine
BRAVTPCARB	<i>Trastuzumab brand name removed; Protocol Title updated; AST replaced with ALT; Institutional name updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Paclitaxel and Carboplatin as First-Line Treatment for Advanced Breast Cancer
BRAVTR	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab
BRAVTRAD	<i>Trastuzumab brand name removed; Protocol Title updated; Institutional name updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; AST replaced with ALT; Institutional name and logo updated</i>	-----	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer
BRAVTRAP	<i>Trastuzumab brand name removed; Protocol Title updated; AST replaced with ALT; Institutional name updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
BRAVTRVIN	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Vinorelbine
BRLAACD	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide followed by Docetaxel
BRLAACDT	<i>Trastuzumab brand name removed; Protocol Title updated; AST replaced with ALT; Institutional name updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated; AST replaced with ALT; Institutional name and logo updated</i>	<i>Trastuzumab brand name removed; Institutional name and logo updated</i>	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab
BRLATACG	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Neoadjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Paclitaxel followed by Doxorubicin and Cyclophosphamide
BRLATWAC	----	<i>Antiemetics updated</i>	----	Neoadjuvant Therapy for Locally Advanced Breast Cancer using Weekly Paclitaxel followed by Doxorubicin and Cyclophosphamide
GIAVPG	<i>Treatment duration clarified</i>	----	----	First-line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and Cisplatin
GIENDO2	----	<i>Antiemetics updated</i>	----	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and Doxorubicin
GIFIRINOX	----	<i>Antiemetics updated</i>	----	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
GIGAJCPT	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer using Cisplatin and Capecitabine and Radiation Therapy
GIGAVCC	----	<i>Antiemetics updated</i>	----	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using Cisplatin and Capecitabine

Revised Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol	PPO	Patient Handout	Protocol Title
GIGAVCCT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated</i>	<i>Trastuzumab brand name removed</i>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab
GIGAVCFT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added; Antiemetics updated</i>	<i>Typo corrected</i>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Cisplatin, Infusional Fluorouracil and Trastuzumab
GIGAVCOXT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	<i>Trastuzumab brand name removed; Title corrected</i>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab
GIGAVEOCAP	----	<i>Antiemetics updated</i>	----	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer using Epirubicin, Oxaliplatin and Capecitabine
GIGAVEOF	----	<i>Antiemetics updated</i>	----	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer using Epirubicin, Oxaliplatin and Infusional Fluorouracil
GIGAVFFOXT	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	<i>Trastuzumab brand name removed</i>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab
GIGAVRAMT	-----	<i>Chemotherapy section reformatted for clarity; Additional Dose Modification section revised (day 15 removed)</i>	-----	Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly Paclitaxel and Ramucirumab
GIGAVTR	<i>Trastuzumab brand name removed; Protocol Title updated</i>	<i>Trastuzumab brand name removed; Pharmacy Selection Box added</i>	<i>Institutional name and logo updated</i>	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Trastuzumab
GIGECC	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower ½ Esophagus using Epirubicin, Cisplatin and Capecitabine
GIPAJFIROX	----	<i>Antiemetics updated</i>	----	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin

Revised Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol	PPPO	Patient Handout	Protocol Title
GIPNEVER	<i>Protocol Code (U removed) and Eligibility revised</i>	<i>CAP requirement and U in Protocol Code removed</i>	<i>Protocol Code revised (U removed)</i>	Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Everolimus
GIPNSUNI	<i>Protocol Code (U removed) and Eligibility revised; Tests clarified; Institutional name and Contact Physician updated</i>	<i>CAP requirement and U in Protocol Code removed; Tests clarified; Institutional name and logo updated</i>	<i>Protocol Code revised (U removed) and Institutional name and logo updated</i>	Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Sunitinib
GIREGO	<i>Protocol Code (U removed) and Eligibility revised</i>	<i>CAP requirement and U in Protocol Code removed</i>	----	Treatment of Advanced Hepatocellular Carcinoma using Regorafenib
GOBEP	----	<i>Antiemetics updated</i>	----	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer using Bleomycin, Etoposide and Cisplatin
GOCISP	----	<i>Antiemetics updated</i>	----	Alternative Treatment of Gynecological Malignancies using Cisplatin and Paclitaxel
GOXAJCAT	<i>Antiemetics updated</i>	----	----	Primary Adjuvant Treatment of Adenocarcinoma/ Adenosquamous Cancer of the Cervix with Carboplatin and Paclitaxel Preceding or Following Irradiation with or without Cisplatin
GOEP	----	<i>Antiemetics updated</i>	----	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer using Etoposide and Cisplatin
GOVCIS	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Therapy for Invasive Epithelial Ovarian Cancer using Cisplatin
GOSMCCRT	----	<i>Antiemetics updated (cycle C PPPO); Institutional name and logo updated</i>	----	Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using Paclitaxel, Cisplatin, Etoposide and Carboplatin with Radiation
GUAJPG	----	<i>Antiemetics updated</i>	----	Adjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine
GUAVPG	----	<i>Antiemetics updated</i>	----	Palliative Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine
GUBEP	----	<i>Antiemetics updated</i>	----	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and Cisplatin

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
GUBGEM	<i>Intraoperative dosing added; Eligibility, administration and treatment duration updated</i>	<i>Intraoperative dosing added; Administration and Return Appointment Orders updated</i>	-----	Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer using Gemcitabine
GUBMITO	<i>Intraoperative dosing added; Eligibility, administration and treatment duration updated</i>	<i>Intraoperative dosing added; Administration and Return Appointment Orders updated</i>	-----	Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer using Mitomycin
GUEDPM	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane
GUEP	-----	<i>Antiemetics updated</i>	-----	Therapy for Nonseminoma Germ Cell Cancer using Etoposide-Cisplatin
GUMVAC	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Therapy for Transitional Cell Cancers of the Urothelium using Methotrexate, Vinblastine, Doxorubicin and Cisplatin
GUNAJPG	-----	<i>Antiemetics updated</i>	-----	Neoadjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine
GUPLHRH	<i>Treatment options, institutional name and Contact Physician updated</i>	<i>Treatment options and institutional name and logo updated</i>	-----	Therapy for Prostate Cancer using LHRH Agonist (Goserelin, Leuprolide or Buserelin)
HNAVFUP	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	-----	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer using Fluorouracil and Platinum
HNAVPC	-----	<i>Antiemetics updated</i>	-----	Treatment for Unresectable, Locoregionally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck using Paclitaxel and Cisplatin or Carboplatin
HNAVPD	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Platinum and Docetaxel
HNAVPE	-----	<i>Antiemetics updated; Institutional name and logo updated</i>	-----	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide
HNLAALPRT	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	-----	Treatment of Locally Advanced (Alternate) Head and Neck Cancer using Cisplatin during Radiation Therapy

Revised Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol	PPPO	Patient Handout	Protocol Title
UHNLADCF	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	<i>Antiemetics and fatigue management updated; Institutional name and logo updated</i>	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Docetaxel, Cisplatin and Infusional Fluorouracil
HNLAPRT	<i>Antiemetics updated</i>	<i>Antiemetics updated (short hydration PPPO)</i>	----	Combined Chemotherapy (Cisplatin) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
HNNAVFUP	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	----	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using Platinum and Fluorouracil
HNNAVPE	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide
HNNAVPG	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	----	Treatment of Locoregionally Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Gemcitabine
HNNLAPG	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine
HNSAVFAC	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Palliative Therapy for Advanced Salivary Gland Cancers using Cyclophosphamide, Doxorubicin and Fluorouracil
HNSAVFUP	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	----	Treatment of Advanced Head and Neck Cancer using Cisplatin and Fluorouracil
HNSAVNP	----	<i>Antiemetics updated</i>	----	Treatment of Advanced Salivary Gland Cancers with Cisplatin and Vinorelbine
HNSAVPAC	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Treatment of Advanced Salivary Gland Cancers with Platinum, Doxorubicin and Cyclophosphamide
LUAJNP	----	<i>Antiemetics updated</i>	----	Adjuvant Cisplatin and Vinorelbine following Resection of Non-Small Cell Lung Cancer
LUAVDC	----	<i>Antiemetics updated</i>	----	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Cisplatin and Docetaxel
LUAVPG	----	<i>Antiemetics updated</i>	----	Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Gemcitabine

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
LUAVPP	----	<i>Antiemetics updated</i>	----	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed
LUMMPG	----	<i>Antiemetics updated</i>	----	Treatment of Malignant Mesothelioma with Platinum and Gemcitabine
LUMMPP	----	<i>Antiemetics updated</i>	----	Treatment of Malignant Mesothelioma with Platinum and Pemetrexed
LUOTCAV	----	<i>Antiemetics updated</i>	----	Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, Doxorubicin and Vincristine
LUOTPAC	----	<i>Antiemetics updated</i>	----	Treatment of Thymoma with Platinum, Doxorubicin and Cyclophosphamide
LUSCAV	----	<i>Antiemetics updated</i>	----	Treatment of Extensive Small Cell Lung Cancer with Cyclophosphamide, Doxorubicin and Vincristine
LUSCPI	----	<i>Antiemetics updated</i>	----	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer with Irinotecan with or without Platinum
LYABVD	----	<i>Antiemetics updated</i>	----	Treatment of Hodgkin's Disease with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine
ULYBRENTUX	<i>Eligibility clarified; Institutional name updated</i>	----	----	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin
LYCHOP	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine and Prednisone
LYCHOPR	<i>Eligibility updated</i>	<i>Antiemetics updated</i>	----	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab
LYCHOPRMTX	<i>Alkalinization regimen revised</i>	<i>Antiemetics updated</i>	----	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma
LYCODOXMR	<i>Antiemetics updated; Cycle interval clarified; Tests revised</i>	<i>Antiemetics updated; Tests revised</i>	----	Treatment of Burkitt's Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin and Rituximab

Revised Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol	PPPO	Patient Handout	Protocol Title
LYEPOCHR	<i>Eligibility and Tests revised; Filgrastim dose and IT methotrexate interval clarified</i>	<i>Antiemetics updated; IT procedure and IT methotrexate interval clarified</i>	----	Treatment of Lymphoma with Dose-Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate
LYGDP	<i>Antiemetics updated</i>	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Cisplatin
LYGDPR	<i>Antiemetics updated</i>	<i>Antiemetics updated</i>	----	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Cisplatin with Rituximab
LYHDMTXR	<i>Protocol Title and Eligibility revised</i>	----	----	Treatment of Secondary CNS Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High-Dose Methotrexate
LYIVACR	<i>Cycle interval clarified; Tests revised</i>	<i>Tests revised; Signature requirement and IT procedure clarified</i>	----	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab
ULYNIV	<i>Exclusions and Tests updated</i>	<i>Tests updated</i>	----	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Nivolumab
ULYNIV4	<i>Exclusions and Tests updated</i>	<i>Tests updated</i>	----	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 4-Weekly Nivolumab
ULYVENETO	----	----	<i>Duration for allopurinol and hydration clarified</i>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax
ULYVENETOR	<i>Eligibility clarified</i>	----	<i>Duration for allopurinol and hydration clarified</i>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Rituximab
UMYDARBD	----	<i>Typo corrected (cycle 1 PPPO); Cyclophosphamide cycles clarified (cycle 2+ PPPO)</i>	----	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide
SAAI	<i>Antiemetics updated</i>	----	----	Therapy for Advanced Soft Tissue Sarcoma using Doxorubicin and Ifosfamide-Mesna
SAAI3	<i>Antiemetics updated</i>	----	----	3-Day Doxorubicin-Ifosfamide-Mesna for Use in Patients with Advanced Soft Tissue Sarcoma
SAAJADIC	----	<i>Antiemetics updated</i>	----	Adjuvant Treatment of Patients with Soft Tissue Sarcoma using Doxorubicin and Dacarbazine

Revised Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol	PPPO	Patient Handout	Protocol Title
SAAJAP	<i>Antiemetics updated</i>	----	----	Adjuvant Therapy for Osteosarcoma using Doxorubicin and Cisplatin
SAAVADIC	----	<i>Antiemetics updated</i>	----	Treatment of Patients with Soft Tissue Sarcoma using Doxorubicin and Dacarbazine
SAAVAP	<i>Antiemetics updated</i>	----	----	Therapy of Advanced Osteosarcoma using Doxorubicin and Cisplatin
SAAVGR	<i>Protocol Code (U removed) and Eligibility revised</i>	<i>CAP requirement and U in Protocol Code removed</i>	----	Third-Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST) using Regorafenib
SAAVI	<i>Antiemetics updated</i>	----	----	Therapy for Advanced Soft Tissue Sarcoma using Ifosfamide
SAAVI3	<i>Ifosfamide/mesna administration updated (separate bags via Y-site); Antiemetics updated</i>	----	----	3-Day Ifosfamide for Use in Patients with Advanced Soft Tissue Sarcoma
SAAVIME3	<i>Ifosfamide/mesna administration updated (separate bags via Y-site); Antiemetics updated</i>	----	----	3-Day Etoposide & Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas
SADTIC	----	<i>Antiemetics updated</i>	----	High-Dose Single Agent Dacarbazine for Metastatic Soft Tissue Sarcoma
SAIME	----	<i>Antiemetics updated</i>	----	Etoposide, Ifosfamide-Mesna for Use in Sarcomas
SANADENO	<i>Protocol Code (U removed) and Eligibility revised</i>	<i>CAP requirement and U in Protocol Code removed</i>	----	Denosumab for Neoadjuvant Use in Patients with Non-Metastatic Operable Giant Cell Tumour of the Bone
SATEMBEV	<i>Protocol Code (U removed) and Eligibility revised</i>	<i>CAP requirement and U in Protocol Code removed</i>	----	Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma using Temozolomide and Bevacizumab
SAVAC	----	<i>Antiemetics updated</i>	----	Treatment of Sarcomas with Vincristine, Doxorubicin and Cyclophosphamide
SAVDC	----	<i>Antiemetics updated</i>	----	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide
SAVDCM	----	<i>Antiemetics updated</i>	----	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin, Cyclophosphamide and Mesna

Revised Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol	PPPO	Patient Handout	Protocol Title
SCNAUSEA	<i>Netupitant-palonosetron information added; Prophylactic Antiemetic Regimens table updated</i>	----	----	Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults
USMAJNIV	<i>Typo corrected (in Exclusions)</i>	-----	-----	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using Nivolumab
USMAJNIV4	<i>Typo corrected (in Exclusions)</i>	-----	-----	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using 4-Weekly Nivolumab
USMAVPEM	-----	<i>Return Appointment Orders updated</i>	-----	Treatment of Unresectable or Metastatic Melanoma using Pembrolizumab
SMDTIC	----	<i>Antiemetics updated; Institutional name and logo updated</i>	----	Therapy for Metastatic Malignant Melanoma using High-Dose Single-Agent Dacarbazine

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor Pharmacy Oncology Certification Nurse Educators	604-877-6275 250-519-5500 x 693742 250-712-3900 x 686820 604-877-6000 x 672638	druginfo@bccancer.bc.ca nbadry@bccancer.bc.ca rxchemocert@bccancer.bc.ca nursinged@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Program	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@ehcnet.phsa.ca mclin@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Sally Waignein, BScPharm, PharmD
Mario de Lemos, PharmD, MSc(Oncol)

Caroline Lohrisch, MD
Jennifer Pesut, RN, BScN
Naren Bollipalli, BSc(Pharm)